Direkt zum Inhalt
Merck

SMB00950

Sigma-Aldrich

O-Desmethyl gefitinib

≥95%

Synonym(e):

4-[(3-Chloro-4-fluorophenyl)amino]-6-[3-(4-morpholinyl)propoxy]-7-quinazolinol, O-Desmethylgefitinib

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C21H22ClFN4O3
CAS-Nummer:
Molekulargewicht:
432.88
UNSPSC-Code:
12352205
NACRES:
NA.77

Biologische Quelle

synthetic

Qualitätsniveau

Qualität

research grade

Assay

≥95%

Form

solid

Methode(n)

HPLC: suitable

Farbe

light yellow to yellow

Lagertemp.

−20°C

InChI

1S/C21H22ClFN4O3/c22-16-10-14(2-3-17(16)23)26-21-15-11-20(19(28)12-18(15)24-13-25-21)30-7-1-4-27-5-8-29-9-6-27/h2-3,10-13,28H,1,4-9H2,(H,24,25,26)

InChIKey

IFMMYZUUCFPEHR-UHFFFAOYSA-N

Allgemeine Beschreibung

O-Desmethyl Gefitinib, a key metabolite of the anticancer drug gefitinib, belongs to the quinazoline family and is present in human plasma. Its formation is facilitated by the cytochrome P450 isoform CYP2D6. This compound exhibits significant activity as an inhibitor of tyrosine residue phosphorylation in EGFR, with an IC50 of 36 nM in subcellular assays. While its effectiveness is comparable to that of gefitinib, O-Desmethyl Gefitinib shows slightly reduced activity in whole-cell assays, with an IC50 of 760, in contrast to gefitinib′s 49 nM. Studies conducted in LoVo tumor mouse xenograft models have revealed that the tumor concentration of O-Desmethyl Gefitinib is notably lower than that of gefitinib, without causing a substantial reduction in tumor growth. Remarkably, increased plasma concentrations of O-Desmethyl Gefitinib in individuals homozygous for CYP2D6 do not lead to an increase in adverse effects. O-Desmethyl Gefitinib holds promise for biochemical and biomedical research, providing potential insights into drug development and cancer treatment.

Anwendung

O-Desmethyl Gefitinib finds application in metabolomics and drug discovery research, particularly in the investigation of cancer and tumor management.

Biochem./physiol. Wirkung

O-Desmethyl gefitinib is generated by the removal of a methyl group from gefitinib during the body′s metabolic processing of this compound within the body.

Leistungsmerkmale und Vorteile

  • High quality compound suitable for multiple research applications
  • Compatible with a wide variety of chromatographic and spectrometry techniques

Sonstige Hinweise

For additional information on our range of Biochemicals, please complete this form.
This product is intended for research purposes only, and it is not meant for human consumption.

Piktogramme

Exclamation mark

Signalwort

Warning

Gefahreneinstufungen

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition
McKillop et al.
Xenobiotica, 36, 29-39 (2006)
Hiroyuki Kobayashi et al.
Medical oncology (Northwood, London, England), 33(6), 57-57 (2016-05-08)
We investigated the effects of polymorphisms in CYP2D6, ABCB1, and ABCG2 and the side effects induced by gefitinib on the pharmacokinetics of O-desmethyl gefitinib, the active metabolite of gefitinib. On day 14 after beginning therapy with gefitinib, plasma concentrations of
Ping Fang et al.
Drug design, development and therapy, 11, 1283-1290 (2017-05-04)
Cytochrome P450 2D6 (CYP2D6), a member of the CYP450 enzyme super family, is a polymorphic enzyme that metabolizes ~25% of therapeutic drugs. CYP2D6 exhibits significant genetic polymorphisms which might cause adverse effects and therapeutic failures of some drugs. The purpose
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man
McKillop et al.
Xenobiotica, 34, 917-934 (2004)
D McKillop et al.
Xenobiotica; the fate of foreign compounds in biological systems, 34(10), 901-915 (2005-03-15)
The pharmacokinetics of gefitinib and its metabolites in rat and dog were investigated in preclinical studies conducted to support the safety evaluation and clinical development of gefitinib, the first EGFR tyrosine kinase inhibitor approved for the treatment of non-small-cell lung

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.